Fresh off Medicare win, CardioDx lines up $58 million financing round

CardioDx Inc. lined up $58 million in a two-tranche round – about $30 million now and the remainder later this year – as it expands following recently won Medicare coverage of its heart disease diagnostic test. Singapore-based investor Temasek joined a slew of existing CardioDx backers, including Kleiner Perkins Caufield & Byers, Mohr Davidow Ventures, TPG Biotech and GE Capital, in the financing, the Palo Alto company said Monday.